Patents Assigned to Biogen Idec
  • Neublastin expression constructs
    Patent number: 7598059
    Abstract: A method of producing a secreted neublastin polypeptide using a heterologous signal sequence is disclosed. The secreted neublastin does not contain a neublastin pro sequence.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: October 6, 2009
    Assignee: Biogen Idec MA Inc.
    Inventors: Nels E. Pederson, William P. Sisk
  • KIM-1 antagonists and use to modulate immune system
    Patent number: 7597887
    Abstract: The use of KIM-1 antagonists to inhibit signaling between a T cell and a second cell, e.g., an antigen-presenting cell, is disclosed. Such inhibition is useful for treatment of diseases including various autoimmune diseases and graft-versus-host disease. Also disclosed is the use of a KIM-1 antagonist to inhibit secretion of IFN-? by lymphocytes or other immune cells in a mammal. Inhibition of IFN-? is useful for treatment of inflammatory diseases or disorders, e.g., inflammatory bowel disease.
    Type: Grant
    Filed: December 29, 2003
    Date of Patent: October 6, 2009
    Assignee: Biogen Idec MA Inc.
    Inventor: Paul D. Rennert
  • DNA sequences, recombinant DNA molecules and processes for producing human fibroblast interferon-like polypeptides
    Patent number: 7588755
    Abstract: DNA sequences, recombinant DNA molecules and hosts transformed with them which produce polypeptides displaying a biological or immunological activity of human fibroblast interferon, the genes coding for these polypeptides and methods of making and using these DNA sequences, molecules, hosts, genes and polypeptides. The DNA sequences are characterized in that they code for a polypeptide displaying a biological or immunological activity of human fibroblast interferon. In appropriate hosts these DNA sequences and recombinant DNA molecules permit the production and identification of genes and polypeptides displaying a biological or immunological activity of human fibroblast interferon and their use in antiviral and antitumor or anticancer agents.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: September 15, 2009
    Assignee: Biogen Idec MA Inc.
    Inventor: Walter Charles Fiers
  • RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY
    Publication number: 20090226430
    Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).
    Type: Application
    Filed: February 29, 2008
    Publication date: September 10, 2009
    Applicant: Biogen Idec Inc.
    Inventors: Nabil HANNA, Roland Anthony Newman, Mitchell Elliot Reff
  • Active lymphotoxin-? receptor immunoglobulin chimeric protein compositions
    Patent number: 7585946
    Abstract: Methods for high level expression of active lymphotoxin-? receptor immunoglobulin chimeric proteins and their purification.
    Type: Grant
    Filed: January 23, 2001
    Date of Patent: September 8, 2009
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey Browning, Konrad Miatkowski, Werner Meier
  • Platelet Aggregation Assays
    Publication number: 20090220998
    Abstract: The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto.
    Type: Application
    Filed: November 17, 2006
    Publication date: September 3, 2009
    Applicant: Biogen Idec MA Inc.
    Inventors: Yen-Ming Hsu, Lihe Su
  • RECOMBINANT ANTI-CD4 ANTIBODIES FOR HUMAN THERAPY
    Publication number: 20090221036
    Abstract: Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity, reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).
    Type: Application
    Filed: July 2, 2008
    Publication date: September 3, 2009
    Applicant: Biogen Idec Inc.
    Inventors: Nabil Hanna, Roland Anthony Newman, Mitchell Elliot Reff
  • ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20090221821
    Abstract: The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable.
    Type: Application
    Filed: February 10, 2009
    Publication date: September 3, 2009
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Carol L. Ensinger, James E. Dowling, Russell C. Petter, Gnanasambandam Kumaravel
  • Cripto-specific antibodies
    Patent number: 7582299
    Abstract: The invention provides Cripto-specific antibodies, or biologically functional fragments thereof, and uses thereof. Antibodies which bind Cripto and inhibit Cripto activity are provided. Antibodies which bind Cripto and inhibit the interaction between Cripto and ALK4 and/or between Cripto and Activin B are provided. Antibodies which bind Cripto and inhibit tumor growth are also provided. Antibodies which bind Cripto, inhibit Cripto activity, and inhibit tumor growth are also provided. The invention also provides methods of using these antibodies in therapeutic, diagnostic, and research applications.
    Type: Grant
    Filed: September 20, 2004
    Date of Patent: September 1, 2009
    Assignee: Biogen Idec MA Inc.
    Inventors: Michele Sanicola-Nadel, Heather Adkins, Steven Donald Miklasz, Paul Rayhorn, Susan Gail Schiffer, Kevin P. Williams
  • NOGO Receptor Antagonists
    Publication number: 20090215691
    Abstract: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same.
    Type: Application
    Filed: December 15, 2008
    Publication date: August 27, 2009
    Applicants: Yale University, Biogen Idec MA Inc.
    Inventors: Daniel H.S. Lee, R. Blake Pepinsky, Weiwei Li, Jane K. Relton, Dane S. Worley, Stephen M. Strittmatter, Dinah W.Y. Sah, Sylvia A. Rabacchi
  • Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders
    Patent number: 7579001
    Abstract: The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: August 25, 2009
    Assignee: Biogen Idec MA Inc
    Inventor: Paul Rennert
  • ANTI-GFRALPHA3 ANTIBODIES
    Publication number: 20090202562
    Abstract: Antibodies and antibody fragments that bind to the receptor GFRalpha3 and inhibit formation of a Neublastin-GFRalpha3-Ret ternary complex are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit phosphorylation of Ret in a cell and treat disorders and in a subject.
    Type: Application
    Filed: June 16, 2006
    Publication date: August 13, 2009
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Dane S. Worley, Dinah Wen-Yee Sah, Katherine W. Seamans
  • TREATMENT FOR MULTIPLE SCLEROSIS
    Publication number: 20090202527
    Abstract: Methods of treating multiple sclerosis and other disorders are disclosed.
    Type: Application
    Filed: November 18, 2005
    Publication date: August 13, 2009
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Michael Panzara, Alfred Sandrock
  • Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
    Patent number: 7569362
    Abstract: The invention provides a method of producing multiple polypeptides, such as antibodies or antibody fragments, in a eukaryotic cell using a single expression vector. The expression vector is engineered to comprise two or more expression cassettes under the control of a single promoter wherein the expression cassettes have splice sites which allow for their alternative splicing and expression as two or more independent gene products at a desired ratio. Use of the vector for the efficient expression of recombinant antibodies in eukaryotic host cells is disclosed as well as the use of such antibodies in diagnostic and therapeutic applications.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: August 4, 2009
    Assignee: Biogen Idec MA Inc.
    Inventor: Holly Prentice
  • Tumor necrosis factor related ligand
    Patent number: 7566769
    Abstract: Tumor Necrosis Factor Related Ligand (TRELL) polypeptides, a novel member of the tumor necrosis factor family (TNF) and compositions comprising them are disclosed.
    Type: Grant
    Filed: June 20, 2006
    Date of Patent: July 28, 2009
    Assignees: Biogen Idec MA Inc., The Faculty of Medicine of the University of Geneva
    Inventors: Jeffrey Browning, Yves Chicheportiche
  • Anti-Alpha V Beta 6 Antibodies
    Publication number: 20090186036
    Abstract: Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having O06-mediated diseases, or to diagnose % Qmediated diseases.
    Type: Application
    Filed: October 29, 2008
    Publication date: July 23, 2009
    Applicants: Biogen Idec MA Inc., The Regents of the University of California, a California corporation
    Inventors: Shelia M. Violette, Paul H. Weinreb, Kenneth J. Simon, Dean Sheppard, Diane R. Leone
  • Oligodendrocyte-Myelin Glycoprotein Compositions and Methods of Use Thereof
    Publication number: 20090175846
    Abstract: The present invention is based on the discovery that oligodendrocyte-myelin glycoprotein (OMgp), which is ex-pressed by oligodendrocytes and CNS myelin, negatively regulates oligodendrocyte and neuronal differentiation and survival. Based on these discoveries, the invention relates generally to methods of promoting neuronal and oligodendrocyte survival and differentiation by administration of an OMgp anatagonist. Additionally, the invention generally relates to methods of treating various diseases, disorders or injuries associated with demyelination, dysmyelination, oligodendrocyte/neuronal cell death, axonal injury and/or differentiation by the administration of an OMgp antagonist.
    Type: Application
    Filed: October 27, 2006
    Publication date: July 9, 2009
    Applicant: BIOGEN IDEC MA INC
    Inventors: Sha Mi, R. Blake Pepinsky
  • COMBINATION THERAPY EMPLOYING LYMPHOTOXIN BETA RECEPTOR BINDING MOLECULES IN COMBINATION WITH SECOND AGENTS
    Publication number: 20090175862
    Abstract: This invention features combination therapies that include a composition that activates lymphotoxin-beta receptor signaling in combination with one or more other biologic agents, as well as therapeutic methods.
    Type: Application
    Filed: December 8, 2008
    Publication date: July 9, 2009
    Applicant: Biogen Idec MA Inc.
    Inventors: Erika Lorraine Silverio, Cindy Bottiglio
  • CD23 BINDING MOLECULES AND METHODS OF USE THEREOF
    Publication number: 20090155255
    Abstract: The invention is based, at least in part, on the development of multivalent and stabilized forms of CD23 binding molecules and methods of use thereof for the treatment of immune cell disorders, including leukemias or lymphomas such as CLL.
    Type: Application
    Filed: September 29, 2008
    Publication date: June 18, 2009
    Applicant: Biogen Idec MA Inc.
    Inventors: Scott Glaser, Brian Robert Miller, Alexey Alexandrovich Lugovskoy, Stephen Demarest, Ann Maclaren, William B. Snyder
  • COMPOSITIONS THAT BIND MULTIPLE EPITOPES OF IGF-1R
    Publication number: 20090130105
    Abstract: The instant invention is based, at least in part on the finding that binding molecules which bind to different epitopes within IGF-1R result in improved IGF-1 and/or IGF-2 blocking capabilities when compared to binding molecules that bind to a single IGF-1R epitope. The instant invention provides compositions that bind to multiple epitopes of IGF-1R, for example, combinations of monospecific binding molecules or multispecific binding molecules (e.g., bispecific molecules). Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize IGF-1R signaling are also provided.
    Type: Application
    Filed: August 28, 2008
    Publication date: May 21, 2009
    Applicant: Biogen Idec MA Inc.
    Inventors: Scott Glaser, Stephen Demarest, Brian Robert Miller, Kandasamy Hariharan, Steffan Ho, Jianying Dong, Alexey Alexandrovich Lugovskoy